Loading...
Market
What will be Black Diamond Therapeutics' stock price by March 31, 2025?
3
Resolution / Starting Odds
Less than $20 • 25%
$20 to $29.99 • 25%
$30 to $39.99 • 25%
$40 or more • 25%
Stock market data from financial platforms like Yahoo Finance, Bloomberg, etc.
Story
Black Diamond Therapeutics Announces Initial Phase 2 Data for BDTX-1535 in Recurrent NSCLC with 42% ORR at 200 mg
Sep 23, 2024, 11:02 AM
Black Diamond Therapeutics has announced the initial Phase 2 data for its BDTX-1535 treatment in patients with recurrent EGFRm non-small cell lung cancer (NSCLC). The data, which will be presented in a webcast at today's 8am ET call, demonstrates robust anti-tumor activity. A 200 mg daily dose has been selected for pivotal development, showing a favorable tolerability profile. Preliminary overall response rate (ORR) of 42% was observed in 19 patients with on-target resistance EGFR mutations. The treatment is effective against a broad spectrum of classical, non-classical, and C797S resistance mutations.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Remain within 10% of current price • 25%
Decrease by more than 10% • 25%
Below $0.50 • 25%
$0.50 - $0.99 • 25%
$1.00 - $1.49 • 25%
$1.50 and above • 25%
Below $300 • 25%
$300 to $350 • 25%
$350 to $400 • 25%
Above $400 • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Yes • 50%
No • 50%
Above $10 • 25%
$8-$10 • 25%
$6-$8 • 25%
Below $6 • 25%
Above $25 • 25%
$20-$25 • 25%
$15-$20 • 25%
Below $15 • 25%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%